Please complete this form and list your purchase and sale transaction(s) for Impax Laboratories, Inc.(NASDAQ: IPXL) securities between February 20, 2014 and November 2, 2016, both dates inclusive (the “Class Period”):
You may also contact Jon Naji, Esq. at (484) 270-1453; or you may submit your information via email at email@example.com, or you may click here to print a PDF of this form.
On November 11, 2016, the initial complaint in this securities class action was filed against Impax Laboratories, Inc. (“Impax” or the “Company”), and certain of Impax’s directors and officers, asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act. This is a federal securities class action brought on behalf of all persons who purchased or otherwise acquired Impax’s common stock between February 20, 2014 and November 2, 2016, (“Class Period”) both dates inclusive.
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Impax and several of its pharmaceutical industry peers colluded to fix generic drug prices; (2) the foregoing conduct constituted a violation of U.S. antitrust laws; (3) consequently, Impax’s revenues during the class period were in part the result of illegal conduct; and (4) as a result of the foregoing, Impax’s public statements were materially false and misleading at all relevant times.
Current Status of Case:
The Court granted Defendant’s Motion to Dismiss on August 12, 2019. Lead Plaintiff filed an Appeal on September 5, 2019. On July 30, 2021, Lead Plaintiff filed a Motion for Preliminary Approval of Settlement. On November 22, 2021, the Court granted Preliminary Approval of the Settlement. A final settlement hearing is set for March 31, 2022. This action is still ongoing.
You may find additional information regarding the terms of the settlement and claim filing process at www.impaxsecuritiessettlement.com, or by calling JND Legal Administration, at 1-833-823-0051.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with or via e-mail at firstname.lastname@example.org. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.